Abstract
A series of 1-(aryloxypropyl)-4-(chloroaryl) piperazines have been synthesized based upon their physicochemical similarity with respect to standard atypical antipsychotic drugs and their potential to cross the blood–brain barrier (log BB) as calculated by appropriate software programmes. The target compounds were evaluated for atypical antipsychotic activity in apomorphine-induced mesh climbing and stereotypy assays in mice. The compounds 8, 9 and 10 bearing hydrogen bond acceptor substituents have emerged as important lead compounds showing higher efficacy along with potential atypical antipsychotic profile.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
